01244nas a2200445   4500000000100000000000100001000000100002008004100003653001100044653002500055653001100080653000900091653001600100653000900116653003400125653004800159653001000207653004700217653004700264653004000311653002200351653002800373653001300401653001900414653002400433653002500457100001300482700001200495700001400507700001400521700001300535700001400548700001400562700001400576245016400590250001500754300000800769490000700777020001400784       2024                            d10aHumans10aCase-Control Studies10aFemale10aMale10aMiddle Aged10aAged10a*Fractures, Bone/epidemiology10a*Gabapentin/adverse effects/therapeutic use10aAdult10aPregabalin/adverse effects/therapeutic use10aAnalgesics/adverse effects/therapeutic use10aArthritis/drug therapy/epidemiology10aAged, 80 and over10aAxial spondyloarthritis10afracture10aGabapentinoids10aPsoriatic arthritis10arheumatoid arthritis1 aI. Scott1 aN. Daud1 aJ. Bailey1 aH. Twohig1 aS. Hider1 aC. Mallen1 aK. Jordan1 aS. Muller00aGabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum  a2024/12/12  a5750 v22  a1741-7015